Curated News
By: NewsRamp Editorial Staff
October 07, 2026
XORTX Therapeutics Targets $700M Gout Market with XORLO
TLDR
- XORTX targets a $700 million annual market with XORLO, potentially capturing share from current gout treatments that have adherence challenges.
- XORTX's XORLO uses a liposomal delivery system to enhance oral absorption of oxypurinol, enabling lower doses and fewer side effects.
- XORTX's XORLO could offer gout sufferers a better-tolerated treatment, improving quality of life and reducing healthcare burdens.
- Gout cases are projected to rise over 70 percent by 2050, and XORTX is developing XORLO to address this growing need.
Impact - Why it Matters
With gout cases projected to skyrocket and current treatments often intolerable, XORTX's XORLO could offer a safer, more effective alternative that improves patient adherence and quality of life. If approved, it would address a critical gap in care for millions suffering from this debilitating disease, potentially reducing healthcare costs and lost productivity while providing a much-needed option for those who cannot tolerate existing therapies.
Summary
Gout, a painful and chronic form of inflammatory arthritis, is set to surge globally over the next 25 years due to aging populations, obesity, and lifestyle choices. In the U.S. alone, over 9 million people have been diagnosed, and a staggering 44 million have elevated uric acid levels, putting them at risk. Current treatments, primarily oral xanthine oxidase inhibitors (XOIs), are effective but often come with severe side effects such as gastrointestinal issues, kidney toxicity, and cardiovascular risks, leading to poor patient adherence. This creates an urgent need for better options.
Enter XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company developing XORLO™, a proprietary formulation of oxypurinol. XORLO utilizes a liposomal delivery system to overcome the historically poor oral absorption of oxypurinol, allowing for lower, better-tolerated doses that effectively lower uric acid without the toxic-level exposure and severe GI side effects of traditional high-dose therapies. The company recently announced the launch of drug material and tablet manufacturing to support a planned two-part clinical study, XRX-OXY-102, based on positive prior results and discussions with the FDA.
XORTX is also working toward a new drug application (NDA) submission to the FDA for XORLO, with a new IND planned for the fourth quarter of 2026. If the two-part trial is successful, XORTX intends to request a pre-NDA meeting and prepare an NDA submission while engaging in pre-commercialization activities. The company targets an NDA submission in about one year and estimates a $700 million annual market opportunity for XORLO. “Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program,” said Allen Davidoff, Co-CEO of XORTX. “It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option.” As gout prevalence rises, XORTX is positioning itself to address a significant unmet need. To learn more about XORTX, click here.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, XORTX Therapeutics Targets $700M Gout Market with XORLO
